A 21-year-old Caucasian man with a diagnosis of Crohn's disease (CD) at the age of 14 was admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) maintenance therapy. His symptoms remained virtually unchanged following high dose corticosteroid therapy. Seven days later, combination therapy with ADA plus intensive granulocyte/monocyte adsorptive apheresis (GMA) was initiated, which induced clinical remission. Therefore, combination therapy with ADA plus intensive GMA appears to be an effective therapeutic option for patients with severe CD while under scheduled ADA maintenance therapy.
Introduction
Crohn's disease (CD) is a chronic, progressive, transmural inflammation of the alimentary tract, which often responds poorly to current pharmacological interventions. In patients with CD, clinical manifestations that reflect a recurrenceremission cycle frequently cause serious complications like fistulae, abscesses and strictures, which result in worsening of the patient's quality of life. Treatment with anti-tumour necrosis factor (TNF)-α antibodies like infliximab (IFX) and adalimumab (ADA, a fully human monoclonal IgG1 antibody) can induce mucosal healing in the affected segments of the digestive tract and change the clinical course of CD (1) . Accordingly, ADA has validated therapeutic efficacy in patients with CD (2) (3) (4) . However, the clinical responses to ADA are often diminished during scheduled maintenance therapy, and consequently, patients develop flare-ups (5) .
Granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn (JIMRO, Takasaki, Japan) is another effective and safe therapeutic option for patients with inflammatory bowel diseases refractory to pharmacological therapy (6-9) including patients with CD or with ulcerative colitis (UC). Further, intensive GMA, involving two sessions per week has recently been shown to be superior to routine weekly GMA both in remission rate and time to remission in patients with refractory UC (9) . Likewise, intensive GMA treatment is reported to induce rapid remission in patients with moderately active UC (9) .
Here, we report a CD case that developed a severe and debilitating flare-up while under scheduled maintenance ADA therapy. The patient was successfully treated with a 
Escherichia coli, Enterobacter species combination of ADA plus intensive GMA.
Case Report
This case was a 21-year-old Caucasian man with previously diagnosed Crohn's disease (CD), colitis type without complications with anal or intestinal fistula. The patient had developed CD at the age of 14 in the United Stated (US) and was admitted to our hospital in September 2010 receiving continued treatment for his CD while in Japan. He had an appendectomy due to appendicitis at the age of 20. The patient was a non-smoker and did not have a family history of IBD. Oral mesalamine (2,400 mg/day), 50 mg/day 6-mercaptopurine (6-MP), discontinued after one year, 750 mg/day metronidazole, and 5 mg to 20 mg/day prednisolone had maintained clinical remission in this case for 7 years. A 160/80/40 mg of ADA induction therapy was initiated in August 2010 in the US following a flare-up that had been refractory to prednisolone. However, a combination therapy with ADA and the aforementioned drugs had rapidly induced and maintained clinical remission. Colonoscopic findings after 8 weeks of ADA treatment revealed scattered erythematous changes within the mucosa extending from the sigmoid colon to the rectum. Prednisolone and metronidazole were tapered from 10 weeks to 16 weeks in line with the improvement of CD activity index (CDAI) after ADA therapy was initiated.
After admission to our hospital, the patient underwent a scheduled maintenance therapy with ADA together with 5 mg/day oral prednisolone and 2,400 mg/day mesalamine. His condition was maintained at clinical remission level; CDAI 93. In January 2011, the patient relapsed with severe abdominal discomfort and, frequent bloody diarrhea while on scheduled ADA maintenance therapy. In Japan, since October 2010, ADA has become available for patients with CD, but ADA dose and interval adjustments are currently not allowed. The patient refused admission to our hospital. Therefore, the prednisolone dose was raised to 15 mg/day. Although his symptoms partially improved, in March 2011, the patient was admitted to our hospital again due to a rapid exacerbation of his symptoms with nausea, anorexia, fever of up to 38 , bloody stool of 10-20 times a day, and weight loss of 5 kg (CDAI 483). Laboratory investigations showed WBC 13,600/μL, RBC 511×10 4 /μL, Hb 12.5 g/dL, ESR (2hr) 44 mm/hr, TP 6.9 g/dL, and CRP 3.96 mg/dL. A negative result was obtained for antigenemia (C-7HRP) test for cytomegalovirus, but Escherichia coli and Enterobacter species were detected in the stool culture (Table 1) . Abdominal computed tomography revealed thickening and edematous changes in the entire colon wall, particularly in the sigmoid colon and the rectum without fistulae or abscesses, and no inflammatory changes in the small intestine. Sigmoidoscopy upon admission on March, 2011 revealed longitudinal ulcers as well as erythematous and edematous changes in the mucosa of the sigmoid colon and the rectum (Fig. 1A) . Immunohistochemical findings on the cytomegalovirus tests on the colon biopsy specimens were also negative. Other pathogenic viruses like rotavirus and norovirus were not analyzed. The patient was intravenously given 60 mg/day prednisolone, 2,400 mg/day oral mesalamine together with total parenteral nutrition (TPN). The patient's condition did not improve, and 7 days after starting intravenous prednisolone administration, the patient was given a combination therapy with ADA (160/80/40 mg every other week) immediately after intensive GMA (two sessions per week). After discussing all other alternative therapeutic options, the patient refused short and long-term treatment with a combination of ADA and azathiopurine (AZA) or 6-MP due to concerns over potential malignancies, like malignant lymphoma and hepatosplenic T-cell lymphoma. His condition rapidly improved in the following weeks of treatment, and clinical remission (CDAI 83) was achieved while tapering the prednisolone dose to 10 mg at week 12 of treatment (Fig. 2) . Twelve weeks after initiating ADA and intensive GMA combination therapy, colonoscopy revealed a marked receding of the longitudinal ulcers, edematous changes and small ulcer in the mucosa of the sigmoid colon. There was healing of the mucosa at all other sites as well (Fig. 1B) . The trough serum ADA levels were 18.2 and 18.0 μg/mL, with a negative detection of anti-adalimumab-antibodies (AAA, Abbott, Germany) at 6 and 10 weeks, respectively. Six months later, the patient continued to be in a stable remission under a treatment regimen consisting of scheduled ADA maintenance therapy, 10 mg/day prednisolone, and 2,400 mg/day mesalamine. 
Discussion
In the clinical setting, the therapeutic options for CD, which has become refractory to ADA are limited. Up to 37% of patients that initially respond to ADA require increases in the dose and interval adjustments over the longterm for maintaining clinical responses. Further, 24.8% of patients per year discontinue therapy due to the loss of response (5). Here, we report a case with a debilitating severe CD, which had relapsed while under scheduled ADA maintenance therapy. The addition of intensive GMA to ADA appeared to be an effective combination therapy that achieved sustained remission in this severe case.
It is now known that antibodies which arise against ADA are associated with the low ADA trough serum concentrations, decreased clinical responses, and finally, the loss of response to this biologic (10) . Although ADA is a fully human monoclonal IgG1 antibody, it is not devoid of immunogenicity. Antibodies against ADA have been reported in 2.6% of patients treated for CD (2) . The serum concentrations of ADA and the presence of AAA had been measured during post-marketing surveillance study for all cases in whom ADA was given for active CD in Japan. In the present case, ADA trough serum concentrations were 18.2 and 18.0 μg/mL following 6 and 10 weeks of treatment, respectively. No AAA was detected when the patient responded well to ADA. The data suggest that the main cause of flareups in this case was not AAA. Indeed, endoscopic findings after the first remission induction with ADA revealed scattered erythematous changes within the mucosa from the sigmoid colon to the rectum. Mucosal healing is generally associated with a reduced risk of flare-ups. The patient had maintained a clinical remission with a potential for flareups, as the patient may not have had complete mucosal healing. In addition, based on the serum levels of ADA at 6 and 10 weeks after re-administration of ADA plus GMA, and AAA being negative, we could assume that the serum level of ADA was adequate to maintain clinical remission in the absence of AAA prior to a flare-up.
Infectious agents such as bacteria and viruses have been linked to the exacerbation of CD (11) . A few stool cultures were analyzed during the disease progression periods and on admission. Only indigenous bacteria, Escherichia coli and Enterobacter species tested positive. Regarding viral infections, cytomegalovirus, norovirus or rotavirus are also reported as risk factors for CD being refractory (12, 13) . Negative antigenemia test against cytomegalovirus (C-7 HRP) was found. Immunohistochemical findings for cytomegalovirus in colon biopsy specimens also tested negative. We did not test for norovirus or rotavirus infections in the present time, but we were aware of alimentary exposure to infection including norovirus or rotavirus within the patient's colonic mucosa susceptible to flare-up. The infection potentially could have triggered the exacerbation of CD in the present case.
Pharmacologic management of CD currently relies on 5-aminosalicylic acid, corticosteroids, immunomodulators (AZA or 6-MP), antibiotics, and TNF-α blockers. Furthermore, in the treatment of patients with CD refractory to ADA, it is recommended that the dose should be increased and interval adjustments be made (3). However, currently, such practices are not allowed in Japan. Additionally, there is little evidence to suggest that switching to IFX induces a rapid and sustained clinical remission. GAIN study reported that the clinical remission rate for patients who switched from IFX to ADA reached a 21% at best (14) , which is not impressive. We thought that switching from ADA to IFX could produce the same response rate, about 20% at best. In contrast, a combination therapy with ADA plus intensive GMA appeared to be an effective option for patients with CD refractory to ADA, especially for patients who wish to avoid immunomodulators due to concerns about serious adverse side effects (15) .
GMA is available in Europe, and Japan for the treatment of patients with active IBD that may have become refractory to standard drug based medication, including TNF-α blockers. GMA depletes elevated and activated myeloid lineage leucocytes and has been associated with a marked downregulation of inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8, and TNF-α, which are released by myeloid leucocytes and lymphocytes, most likely via an upstream mechanism that involves adsorption of cytokineproducing cells (1, 16, 17) . The clinical outcomes in a recent case report (18) showed that as a non-drug based intervention, weekly GMA when added to scheduled IFX maintenance therapy was effective in a CD patient with active disease while under IFX therapy. This was followed by a similar report (19) indicating that the addition of intermittent weekly GMA to scheduled IFX maintenance was effective in a CD case also refractory to IFX alone. GMA cannot interfere with the serum concentration of TNF-α biologics (20) . Further, intensive GMA involving two sessions per week has been recently shown to be more effective than conventional weekly GMA for refractory IBD (9) . Additionally, as a non-drug therapeutic intervention, GMA does not carry a high risk of serious adverse events. In the present case, the patient's CD was very severe and debilitating in spite of receiving scheduled ADA maintenance therapy. Accordingly, it was essential to induce rapid clinical remission. Based on the outcomes in this very severe case, we thought that a combination therapy with ADA plus intensive GMA, which is safe, should improve the disease in this case.
In conclusion, combination therapy with ADA plus intensive GMA induced a clinical remission in the present case with a severe CD that had relapsed under scheduled ADA maintenance therapy. Accordingly, GMA appears to be an effective adjunct therapy for patients with CD who do not respond well to scheduled maintenance therapy with an anti-TNF-α biologic, those who refuse treatment with immunomodulators, and those with poor tolerance for immunomodulators.
